News and Events

Montreal (Quebec), February 25, 2021—CQDM is proud to announce the launch of a $2,025,077 international collaborative project to support the preclinical stages of new drug candidates to treat an orphan lung disease. Led by Professor David Y. Thomas of McGill University, this multi-partner project focuses on the development of drugs addressing alpha-1 antitrypsin deficiency (A1AT), a condition characterized by lung and liver damage caused by an inherited genetic mutation for which there is currently no treatment. The laboratory of Professor David Y. Thomas at McGill University is receiving a grant of$371,165 from the ministère de l’Économie et de l’Innovation du Québec to execute the project. These funds are provided in addition to contributions from Pfizer and Montreal-based Traffick Therapeutics, support from the Fonds de recherche du Québec—Santé and the Canadian ...